Seeking Alpha

Biogen Idec (BIIB -0.2%) and Elan (ELN -0.5%) submit applications to the FDA and EMA requesting...

Biogen Idec (BIIB -0.2%) and Elan (ELN -0.5%) submit applications to the FDA and EMA requesting labeling updates to Tysabri to expand the indication to include first-line use for people living with relapsing forms of multiple sclerosis who have tested negative for antibodies to the JC virus. If approved, it will allow all anti-JCV antibody negative patients to consider the drug early in the course of treatment, regardless of the level of disease activity or prior treatment history.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs